1. [Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast]
- Author
-
Jean-Marc, Ferrero, Nicolas, Magné, Cyril, Foa, Rémy, Largillier, and Moïse, Namer
- Subjects
Clinical Trials, Phase II as Topic ,Clinical Trials, Phase III as Topic ,Heart Diseases ,Paclitaxel ,Doxorubicin ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Arrhythmias, Cardiac ,Breast Neoplasms ,Female ,Heart - Abstract
Within the past decades there has been major interest in associating the paclitaxel into the management of breast cancer patients with a strong improvement of clinical results. Moreover, doxorubicin is historically one of the major chemotherapeutic agents in breast cancer treatment. So, investigations of the combination of the paclitaxel with doxorubicin have logically taken place in the strategy of breast cancer management. Also, this association became a standard of care neoadjuvantly in locally advanced breast cancer. The aim of this review of literature consists to make a special focus on cardiac toxicity occurring after doxorubicin and paclitaxel association and to give adequate directions for the next future in this promising combination.
- Published
- 2003